Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|March 1, 2003
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-03-01-2003
- Volume 15
- Issue 3
It's the money that counts
Author(s)Albedo
Brussels report
Advertisement
As the introduction of new member states to the European Union edges closer, the debate in Brussels regarding healthcare for the enlarged Union becomes more heated. Health standards in new member states are predicted to increase, but the main worry for the usual protagonists is how will the European pharmaceutical industry fare?
This article is currently available in printed form only.
To ensure access to all articles from every issue of Pharmaceutical Technology Europe
Articles in this issue
over 23 years ago
Standards for Supplementsover 23 years ago
Installing Clean Process Linesover 23 years ago
A Literature Review of Pharmaceutical Process ValidationAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement